Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Protalix Biotherapeutics, Inc. (PLX) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Protalix Biotherapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1006281.
Total stock buying since 2015: $4,662,521.
Total stock sales since 2015: $4,466,038.
Total stock option exercises since 2015: $122.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 129,000 | $205,884 | 0 | $0 | 0 | $0 |
| 2023 | 64,516 | $90,644 | 0 | $0 | 0 | $0 |
| 2022 | 68,000 | $102,000 | 0 | $0 | 0 | $0 |
| 2021 | 0 | $0 | 918,717 | $2,088,538 | 0 | $0 |
| 2020 | 64,000 | $155,264 | 0 | $0 | 0 | $0 |
| 2017 | 50,000 | $40,500 | 0 | $0 | 0 | $0 |
| 2016 | 0 | $0 | 7,500,000 | $2,377,500 | 122,162 | $122 |
| 2015 | 4,010,423 | $4,068,229 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-06 | 129,000 | $205,884 | 0 | $0 | 0 | $0 |
| 2023-10 | 64,516 | $90,644 | 0 | $0 | 0 | $0 |
| 2022-04 | 68,000 | $102,000 | 0 | $0 | 0 | $0 |
| 2021-06 | 0 | $0 | 918,717 | $2,088,538 | 0 | $0 |
| 2020-04 | 64,000 | $155,264 | 0 | $0 | 0 | $0 |
| 2017-05 | 50,000 | $40,500 | 0 | $0 | 0 | $0 |
| 2016-12 | 0 | $0 | 7,500,000 | $2,377,500 | 0 | $0 |
| 2016-09 | 0 | $0 | 0 | $0 | 122,162 | $122 |
| 2015-12 | 10,000 | $7,800 | 0 | $0 | 0 | $0 |
| 2015-10 | 4,000,423 | $4,060,429 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-10 | Schwartz Aharon | Buy | 129,000 | 1.60 | 205,884 |
| 2023-10-19 | Bashan Dror (PRESIDENT AND CEO) | Buy | 64,516 | 1.41 | 90,644 |
| 2022-04-11 | Bashan Dror (President and CEO) | Buy | 68,000 | 1.50 | 102,000 |
| 2021-06-03 | Oren Dan | Sale | 857,506 | 2.25 | 1,931,961 |
| 2021-06-02 | Oren Dan | Sale | 61,211 | 2.56 | 156,577 |
| 2020-04-07 | Schwartz Aharon | Buy | 64,000 | 2.43 | 155,264 |
| 2017-05-16 | Manor Moshe (President & CEO) | Buy | 50,000 | .81 | 40,500 |
| 2016-12-02 | Camber Capital Management Llc (10% Owner) | Sale | 5,000,000 | .32 | 1,585,000 |
| 2016-09-15 | Shaaltiel Yoseph (Executive VP, R&D) | Option Ex | 122,162 | .00 | 122 |
| 2015-12-14 | Maimon Yossi (Vice President & CFO) | Buy | 10,000 | .78 | 7,800 |
| 2015-10-19 | Camber Capital Management Llc | Buy | 4,000,423 | 1.01 | 4,060,429 |
Insider trading activities including stock purchases, stock sales, and option exercises of PLX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Protalix Biotherapeutics, Inc. (symbol PLX, CIK number 1006281) see the Securities and Exchange Commission (SEC) website.